secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-241963
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill
------------------------------------------------------------------------

- Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).
- Loan amendment: Avenue converts $6M debt into 12.5M shares and warrants on same PIPE terms.
- Collaboration with Chugai: $10M upfront, up to $18M tech transfer, $57M development, $100M sales milestones, plus royalties.
- Samsara and Anomaly get board appointment rights if each holds ≥25% of its PIPE securities.
- Warrants exercisable five years post-stockholder approval; pre-funded warrants exercisable immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312525241963/0001193125-25-241963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312525241963/d38236d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer